Straumann Group Reports Strong Growth in Q2 2024 and Adjusts Outlook After Selling DrSmile

Straumann Group announced robust financial results for the first half of 2024, with a half-year revenue of CHF 1.3 billion, reflecting an organic growth of 16.1%. In the second quarter alone, revenue reached CHF 654.9 million, a 14.8% increase. Despite currency headwinds, the core EBIT margin held steady at 27.8%.

The sale of DrSmile to Impress Group marks a significant strategic shift, with Straumann retaining a 20% minority stake in the new entity. This move positions Impress Group to lead in Europe’s direct-to-consumer clear aligner market while Straumann focuses more on its go-to-market activities.

Regionally, Asia Pacific led growth with 33.8%, followed by Latin America at 14.9%, EMEA at 12.4%, and North America at 5.3%. The Group also emphasized significant investments in digital transformation and education, particularly through the ITI World Symposium held in Singapore.